International Journal of Polymer Science

International Journal of Polymer Science / 2016 / Article

Review Article | Open Access

Volume 2016 |Article ID 7697031 |

Marta Szekalska, Agata Puciłowska, Emilia Szymańska, Patrycja Ciosek, Katarzyna Winnicka, "Alginate: Current Use and Future Perspectives in Pharmaceutical and Biomedical Applications", International Journal of Polymer Science, vol. 2016, Article ID 7697031, 17 pages, 2016.

Alginate: Current Use and Future Perspectives in Pharmaceutical and Biomedical Applications

Academic Editor: Muhammet U. Kahveci
Received26 Sep 2016
Revised16 Nov 2016
Accepted05 Dec 2016
Published28 Dec 2016


Over the last decades, alginates, natural multifunctional polymers, have increasingly drawn attention as attractive compounds in the biomedical and pharmaceutical fields due to their unique physicochemical properties and versatile biological activities. The focus of the paper is to describe biological and pharmacological activity of alginates and to discuss the present use and future possibilities of alginates as a tool in drug formulation. The recent technological advancements with using alginates, issues related to alginates suitability as matrix for three-dimensional tissue cultures, adjuvants of antibiotics, and antiviral agents in cell transplantation in diabetes or neurodegenerative diseases treatment, and an update on the antimicrobial and antiviral therapy of the alginate based drugs are also highlighted.

1. Introduction

Alginates (ALG) are a group of naturally occurring anionic polysaccharides derived from brown algae cell walls, including Macrocystis pyrifera, Laminaria hyperborea, Ascophyllum nodosum [1, 2], and several bacteria strains (Azotobacter, Pseudomonas) [3]. This term usually referred to alginic acid and its salts, but it can also be used for all derivatives of alginic acid. ALG are linear biopolymers consisting of 1,4-linked β-D-mannuronic acid (M) and 1,4 α-L-guluronic acid (G) residues (Figure 1) arranged in homogenous (poly-G, poly-M) or heterogenous (MG) block-like patterns [14]. With regard to the initial source material, commercial ALG may differ in composition and the sequence of G- and M-blocks.

ALG extraction process from seaweeds is uncomplicated but multistage procedure, which usually starts with treating the dried raw material using diluted mineral acid. After further purification, the obtained alginic acid is converted into water-soluble sodium salt in the presence of calcium carbonate, which is next transformed back into acid or its expected salt (Figure 2) [2, 4].

Commercial ALG are exclusively possessed from algal sources, although alternative production by microbial fermentation has been recently explored in order to provide ALG with more defined physicochemical properties [3].

Among various ALG, sodium alginate is one of the most widely investigated ones in the pharmaceutical and biomedical field and its monograph is included into both the European Pharmacopeia and the United States Pharmacopeia [5, 6]. The current pharmacopoeial requirements regarding sodium alginate are presented in Table 1.

ParameterEur. Ph. 8.0USP 32-NF 27

Appearance of solid productWhite or pale yellowish-brown powdern.d.
Contentn.d.90.8%–106.0% of dried basis
Packaging and storagen.d.preserved in tight containers
SolubilitySlowly soluble in water, practically insoluble in ethanol 96%n.d.
Appearance of solutionNot more opalescent than reference formazin suspension in water and not more intensely coloured than intensity 6 of the range of reference solutions of the most appropriate colourn.d.
Heavy metals≤20 ppm≤0.004%
Arsenicn.d.≤1.5 ppm
Loss on drying≤15.0%≤15.0%
Total ashn.d.18.0%–27.0%
Sulfated ash30.0%–36.0%n.d.
Microbial limitsTAMC: ≤1000 cfu/g≤200 cfu/g
TYMC: ≤100 cfu/g
Absence of specified microorganismsSalmonella sp., Escherichia coliSalmonella sp., Escherichia coli

n.d.: not determined, TAMC: total aerobic microbial count, and TYMC: total yeast/moulds count.

2. General Properties of ALG

Currently used ALG possess a high degree of physicochemical heterogeneity which influences their quality and determines potential applicability. ALG are commercially available in various grades of molecular weight, composition, and distribution pattern of M-block and G-block, the factors responsible for their physicochemical properties such as viscosity, sol/gel transition, and water-uptake ability. The molecular weight, expressed as an average of all the molecules present in the sample, of commercial ALG varies between 33 000 and 400 000 g/mol. ALG extracted from different sources differ in M and G residues as well as the length of each block. Generally, by raising the ALG G-block content or molecular weight, more stronger and brittle ALG gels may be achieved [67]. Alginic acid is insoluble in water and organic solvents, whereas ALG monovalent salts and ALG esters are water-soluble forming stable, viscous solutions [14]. The 1% w/v aqueous solution of sodium alginate has a dynamic viscosity 20–400 mPa·s at 20°C. ALG solubility is limited by the solvent pH (a decrease in pH below pKa 3.38–3.65 may lead to polymer precipitation), ionic strength, and the content of “gelling ions” [2, 68]. ALG with more heterogeneous structure (MG-blocks) are soluble at low pH compared to poly-M or poly-G ALG molecules, which precipitate under these conditions [69, 70]. Apart from molecular weight, the ALG capability of creating viscous solutions may vary according to their concentration, solvent pH (a maximum pH is reached around 3.0–3.5), temperature, and the presence of divalent ions [13, 68].

ALG can be easily formed into diverse semisolid or solid structures under mild conditions because of their unique ability of sol/gel transition. Therefore, ALG are commonly used as viscosity increasing agents, thickeners, and suspension and emulsion stabilizers in food and pharmaceutical industry (Table 2).

CodeIngredientApplication in food industryApplication in pharmaceutical industry

E400Alginic acid [1]Emulsifier, formulation aid, stabilizer, thickenerTablet binder and disintegrant, sustained release and release-modifying agent, taste masking agent, thickener, suspending and viscosity increasing agent, stabilizer
E401Sodium alginate [4]Texturizer, stabilizer, thickener, formulation aid, firming agent, flavour adjuvant, emulsifier, surface active agentSuspending and viscosity increasing agent, tablet and capsule disintegrant, tablet binder, stabilizer, sustained release agent, diluent in capsule formulation, thickener
E403Ammonium alginate [7]Stabilizer, thickener, humectantColor diluent, emulsifier, film former, humectant
E404Calcium alginate [8]Stabilizer, thickenerTablet disintegrant
E405Propylene glycol alginate
Emulsifier, flavoring adjuvant, formulation aid, stabilizer, surfactant, thickenerStabilizer, emulsifier, suspending and viscosity increasing agent

ALG gelation can be induced in the presence of divalent ions, which cross-link the polymer chains through the “egg-box” model [68, 71, 72] or by lowering the pH value below the pKa of ALG monomers using lactones like d-glucono-δ-lactone [2, 4]. It should be noted that calcium chloride, most frequently used source of Ca2+ ions, is responsible for rapid and uncontrollable ALG gelation. The gelation rate is a critical parameter in controlling gelation process. Slow gelation provides creating uniform gel structures with mechanical integrity [67]. One approach to reducing the rate of gel forming process is to apply to phosphate buffers (e.g., sodium hexametaphosphate). In the reaction with ALG carboxylate groups, phosphate groups present in the buffer compete with calcium ions and as a result ALG gelation process is retarded [73]. Additionally, calcium sulfate and calcium carbonate with lower solubility also prolong the gel formation. The gelation rate is also dependent on temperature; at lower temperatures, the reactivity of Ca2+ is reduced [74]. Recently, a freeze-thaw technique has been examined as an advanced controlled method for ALG hydrogels formation [75]. Gelling properties are strongly associated with ALG structure and proportions of M-, G-, and MG-blocks [67, 71, 76]. In addition, ALG gels with an increased amount of repeating G-block units are regarded as stiffer, brittle, and mechanically more stable [71, 72]. In contrast, ALG characterized by high proportion of M-blocks form gradually soft and more elastic gels. However, MG-blocks in ALG gel determine its shrinkage and higher flexibility [77]. Nevertheless, ALG with predominated M-block content, as a result of high water absorption, exchange ions more easily in comparison to ALG with higher amount of G-block residues [68, 71, 72, 78]. It should be noted that a number of studies revealed that ALG solution/gel transition occurred under physiological conditions, for example, in the presence of divalent ions and under acidic environment of body fluids [72]. For instance, nonwoven dressings of calcium alginate capable of exchange ions with the wound fluid have been commonly utilized for the treatment of exuding injuries or infected surgical wounds [7981]. Formation of a highly absorbent soluble gel effectively maintains a physiologically moist environment and aids healing process through facilitating growth of fresh epidermis [75, 79]. Due to mechanical stability and proper viscoelastic behavior, ALG are also applied as structural supporting biomaterials for tissue (teeth, bone, and cartilage) reconstruction [79].

The fact that ALG may undergo in situ gelation makes ALG materials promising tools for a wide range of applications, including injectable vehicles for tissue engineering or topical drug delivery systems [41, 79, 82]. Moreover, due to gelling properties, ALG have been investigated as taste masking agents [83, 84]. Studies performed with using potentiometric electronic tongue [85] have proved that spray-dried microspheres with sodium alginate hid the bitter taste of ranitidine hydrochloride through physical gel-barrier formation (Figure 3). Figure 3 presents final chemical image, which shows that for all samples distinctive clusters are easily observable. They are formed by chemical images of samples of various types, where ALG microspheres with ranitidine hydrochloride are easily discernable from pure drug, which indicates masking effect obtained with the use of sodium alginate.

Greatly porous three-dimensional ALG hydrogel structure displays favorable swelling properties arising from the presence of hydrophilic functional groups [86]. ALG ability of hydration and gel formation gives the opportunity to prolong release of the active substance at the administration site. Hence, these polymers have been extensively studied for prolonged or controlled release drug delivery systems [87, 88].

In addition, owing to the mild conditions during gel formation, ALG (especially calcium alginate) appear to be favorable tools for cell entrapment used in tissue engineering or regeneration [8991]. ALG barrier protects immobilized material toward physical stress (maintaining its viability during long-term culture) and enables avoiding immunological reactions with the host. Currently, ALG microparticulate systems are also being developed for the treatment of a variety of diseases, including cancer, diabetes, or Parkinson’s disease [92, 93].

ALG possess good mucoadhesive properties resulting from the presence of free carboxyl groups allowing the polymer to interact with mucin by hydrogen and electrostatic bonding. Environmental pH has a strong impact on ALG solubility and consequently on their mucoadhesive character as only ionized carboxyl groups are capable of interacting with mucosal tissue. In addition, soluble ALG facilitate solvent penetration through polymer matrix resulting in formation of more viscous and cohesive gel structure responsible for strengthening the mucoadhesive bonds. In contrary, too excessive hydration of ALG matrix in physiological fluids might weaken mucoadhesiveness as a result of attenuation of ALG functional groups available for interactions with mucosal tissue [9496].

Owing to mucoadhesive properties, ALG are regarded as proper polymer excipients to prepare buccal [9799], nasal [100, 101], ocular [102, 103], and gastrointestinal dosage forms [104108]. Recently, several studies have shown favourable mucoadhesiveness of ALG-based applications in contact with vaginal mucosa tissue [108, 109]. Furthermore, an increased drug residence time at the ocular mucosal surface and prolonged release of active agents from microparticulate delivery systems with ALG were displayed [110]. Due to large surface area, which may favour an intimate contact between the polymer and mucin, multiunit dosage forms with sodium alginate are also explored as gastroretentive drug carriers (Figure 4), especially for substances, which are unstable or degraded in the alkaline pH [111, 112].

ALG have been extensively evaluated as vaccine adjuvants or coadjuvants as these polymers were displayed to enhance bioavailability and immunogenicity of antigens after nasal and oral administration [101, 113, 114].

3. ALG Modification for Drug Delivery Systems and Biomedical Devices

ALG can be easily modified through chemical or physical cross-linking in order to form ALG hydrogels and improve physicochemical properties and/or biological activity. Many methods have been described for ALG cross-linking, which includes ionic cross-linking, covalent cross-linking, cell cross-linking, phase transition (thermal gelation), “click” reaction, and free radical polymerization [89]. An alteration of the M- to G-block proportion or an enrichment of polymer backbone in M-, G-, or MG-blocks is being practiced by modification through enzymatic epimerisation catalysed by mannuronan C-5 epimerases. This enzyme, isolated from the soil bacterium Azotobacter vinelandii and expressed in Escherichia coli, converts mannuronic acid residues into guluronic acid residues in the polymer backbone without breaking of the glycosidic bond [87, 115, 116]. Additionally, from ALG backbone, oligosaccharides might be isolated, which are polymer fragments containing three to ten of simple monosaccharides. There are two methods, which might be used to prepare ALG oligosaccharides: enzymatic depolymerization and acid hydrolysis [56]. The common chemical modification of ALG hydroxyl groups includes oxidation, sulfation, graft copolymerization, acetylation, and phosphorylation process [117, 118]. Modification of the carboxyl groups may be achieved by esterification and amidation [89, 117, 118]. A list of the commonly used chemical changes of ALG structure for biomedical and pharmaceutical application is presented in Table 3. ALG solubility might be changed by modification of hydroxyl groups (in positions C2 and C3) or the carboxyl groups (in C6 position) through covalent attachment of long alkyl chains or aromatic groups to the polymer backbone. Increasing ALG hydrophobicity provides decreasing polymer dissolution and erosion. Additionally, there are many studies, which include production of ALG derivatives by grafting with different substances such as polyacrylamide, methacrylate, galactose, lectin, sulfate, cysteine, cyclodextrins, propylene glycol, and dodecylamine [117119].

Type of modificationMaterialActive substanceBiomedical or pharmaceutical applicationDosage formReference

OxidationOxidized-NaALGLimbal epithelial stem cellsImprovement of corneal wound healing therapyHydrogel
Wright et al. [10]
FlurbiprofenSustained oral deliveryBeadsMaiti et al. [11]

of oxidized alginate
ALG-g-poly(ethylene glycol)Human foreskin fibroblastsSpecific cell microencapsulationMicrospheresMahou et al. [12]

SulfationSulfated ALGReduction of secretion inflammatory cytokines, improvement of the biocompatibilityMicrospheresArlov et al. [13]

PhosphorylationPhosphorylated ALGMineralization of hydroxyapatite and participation in the chelation process for tissue engineeringGelColeman et al. [14]

Graft copolymerizationNaALG-co-polyacrylamideFamotidineSustained release gastroretentive carrierHydrogelTripathi and Mishra [15]
Starch--poly(acrylic acid)-NaALGDiclofenac sodiumpH-sensitive matrices for the oral drug deliveryHydrogel beadsChang [16]
ALG-glycidyl methacrylate
Human endothelial cell lines HUVEC and L929Thermal polymerizable injectable hydrogel for tissue engineering, especially for myocardial repairHydrogelWang et al. [17]
Galactosylated ALGHepatocytesCell carrier with mechanical stability and selective permeabilityMicrocapsulesTian et al. [18]
α-Cyclodextrin-ALG conjugateSphingomonas cloacaeImmobilization of bacteriaBeadsPluemsab et al. [19]
β-Cyclodextrin-ALG conjugateOndansetronControlled drug delivery systemsGelIzawa et al. [20]

EsterificationPropylene glycol ALGLysozymeProtein encapsulation with a sustained releaseMicroparticlesHurteaux et al. [21]

4. ALG Biological Activity and Application in Pharmaceutical Products

ALG are regarded as biocompatible, nonimmunogenic, and nontoxic materials [2]. Although ALG gel is not degradable in mammalian digestive tract (alginase/lyase enzyme involved in depolymerization of ALG is present only in prokaryotic and eukaryotic microorganisms) [120], it simply dissolves as a result of elution of cross-linking calcium ions. It should be noted that only small ALG molecules are excreted by renal clearance threshold. To enable complete elimination of ALG from the body, partial oxidation of polymer backbone is necessary [121]. ALG biocompatibility was confirmed in vivo after ocular [122], nasal [114], topical [123], local [124, 125], and oral administration [126]. Food and Drug Administration has recently affirmed several ALG salts (calcium, sodium, ammonium, and potassium) as well as propylene glycol ALG derivative as GRAS (generally regarded as safe) ingredients for oral administration [127]. Nevertheless, several data reported that chemical composition of ALG may affect polymers’ immunogenicity. For instance, Otterlei et al. described that ALG with high M-block were much more potent in inducing cytokine production compared with ALG with high G constituents [128]. In addition, various impurities such as heavy metals, endotoxins, proteins, and polyphenol compounds present in ALG material could potentially exert immunogenic response [129, 130]. Therefore, to assure high purity of ALG, proper decontamination methods should be applied concomitantly with extraction procedure [130].

ALG have been extensively studied for a wide range of applications. They include in situ gel formation, controlled release, targeted drug delivery, and medical purposes [2, 87, 88]. List of the pharmaceutical products based on ALG is presented in Table 4.

ProductMain ingredientsDescriptionIndications

Oral administration
Gastrotuss® baby syrup [22, 23]Magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxideCreates a mechanical barrier between the stomach and the esophagus which prevents the reflux, recurrent symptoms of respiratory, choking, dysphagia, heartburn, belching, irritability; accelerates gastric movement, regenerates mucous membranes of the esophagus and ensures its protectionChildren and infants from the first days of life reflux treatment
Algicid® suspension/tablets [24]500 mg sodium alginate, 100 mg potassium bicarbonate per 5 ml/per 1 tabletAdult reflux treatment
Gaviscon Double Action Liquid® [25]250 mg sodium alginate, 106.5 mg sodium bicarbonate, and 162.5 mg calcium carbonate per 5 ml
Gaviscon Double Action tablets® [26]250 mg sodium alginate, 106.5 mg sodium bicarbonate, and 187.5 mg calcium carbonate per tablet

Dermal application
Flaminal Forte® gel [27]Hydrated alginates polymers in a polyethylene glycol (PEG) matrix with a biologic enzyme system based on glucose oxidase and lactoperoxidase stabilized by guaiacolDissolution of dry scab and necrotic material, absorption of lysed material and bacteria by alginates in hydrated formLeg and diabetic ulcers, pressure sores, complex grazes, burns, oncology and wounds dermatosurgery
Purilon Gel® gel [28]Carboxymethylcellulose, calcium alginateProvides moist environment at wound surfaceDry and sloughy necrotic wounds, pressure and venous ulcers, second-degree burns, cuts, abrasions and skin tear, noninfected diabetic foot ulcers
Saf-Gel® gel [29]Carbomer, propylene glycol sodium/calcium alginate
Hyalogran® dressing [30]Ester of hyaluronic acid (HA) and sodium alginateExudate absorbs and transforms to soft gel; removes necrotic tissueVariety of exuding wounds including leg ulcers, pressure sores, ischemic and diabetic wounds, particularly those which are covered with slough and necrotic tissue or areas that are difficult to dress
SeaSorb® dressing [31]Calcium alginateCreates moist environment at wound surface, conversion soft fibres to wet gelHeavily exuding wounds including leg and pressure ulcers, diabetic ulcers and second-degree burns, cavity wounds
Tromboguard® dressing [32]Two-layer dressing built from hydrophilic polyurethane sponges and biologically active layer containing chitosan, sodium alginate, calcium alginate, and silver cationsStrong haemostatic and antibacterial activityControl of bleeding traumatic and postoperative wounds
Fibracol Plus® dressing [32]90% collagen and 10% calcium alginateProvides moist environment at wound surface, tissue granulation, epithelialisation, and healingExuding wounds including: full-thickness and partial-thickness wounds; pressure ulcers; venous ulcers; ulcers caused by mixed vascular etiologies; diabetic ulcers; second-degree burns
Algivon® dressing [33]Calcium alginate dressing impregnated with Manuka honeyBinds of exudate, regenerationSloughy, necrotic, and malodorous wounds
Guardix-SG® [34, 35]Sodium alginate, poloxamer, calcium chlorideCreates thermosensitive viscous gel in contact with body temperature and forms mechanical barrier separates injured tissuesIn spine and thyroid surgeries to reduction of the incidence postoperative adhesions

Rectal administration
Natalsid® suppositories [36]Sodium alginateAnti-inflammatory local actionChronic haemorrhoids, proctosigmoiditis, and chronic anal fissures after surgical interventions in the area of the rectum

Periodontal application
Progenix putty®, Progenix plus® injection [37]Demineralised bone matrix in type-1 bovine collagen and sodium alginateRegeneration, complementation of bone losses; periodontal diseasesBony voids or gaps of the skeletal system
Emdogain® gel [3840]Enamel matrix derivative (EMD), propylene glycol alginateRegeneration, periodontal diseases, paradontosis1-, 2-, and 3-wall intrabony defects, class II mandibular furcation defects with minimal interproximal bone loss, recession defects

Arthroscopic application
ChondroArt 3D™ injection [41]Autologous chondrocytes situated on a hydrogel scaffold built from connection of alginate and agaroseIncrease production and growth of cartilageDegenerative diseases of joints and backbones (osteoarthrosis, osteochondrosis)

ALG are known to act as a physical barrier in order to reduce reflux episodes [131, 132]. A number of available ALG-based pharmaceutical products used for the symptomatic treatment of heartburn and oesophagitis exist [132]. As ALG formulations generally contain bicarbonate salt, it converted to carbon dioxide (entrapped within the gel matrix) enabling polymer to float on the surface of the gastric fluid. ALG-based products may retain in the stomach for several hours providing long-lasting relief [132134]. Several studies revealed that sodium alginate is able to move to the oesophagus ahead of gastric contents and hence might be helpful in decreasing the number of acid esophageal episodes. Additionally, owing to mucoadhesive properties, ALG was demonstrated to protect gastric mucosa from harmful activity of gastric fluid [131, 132, 134]. Antacid ALG products are generally regarded as safe and may be used in children and pregnant women [134].

ALG are also considered as promising candidates in obesity and type 2 diabetes treatment as they are able to attenuate the postprandial glycemic response by modulation of gastric emptying [135138] or inhibition of glucose transporters and glucose intestinal absorption rate [137]. Additionally, there are studies which have also revealed that ALG mode of hypoglycemic action might be associated with the reduced activity of α-amylase, intestinal enzyme responsible for hydrolyzing the bonds between glucose residues in carbohydrate polymers [106, 139].

Superior anti(hyper)lipidemic efficacy of ALG was also displayed. ALG were found to combine bile acids in the digestive tract and to reduce their intestinal reabsorption [140], which in consequence enhance their excretion [141143]. Furthermore, Houghton et al. suggested that ALG are capable of reducing pancreatic lipase activity by protonating active sites in enzyme’s structure [144]. Calcium alginate was also reported to show hypocholesterolemic activity after oral administration as it was found to reduce plasma cholesterol level effectively in the rat model [140].

Numerous data have drawn attention to the use of ALG derivatives as antibacterial, antiviral, and antifungal agents [145, 146]. Several mechanisms have been proposed to explain ALG antimicrobial activity. Negatively charged ALG were found to interact with the outer bacterial cellular surface, leading to its disruption and leakage of intracellular substances [147, 148]. A decrease in membrane function by formation a viscous ALG layer around the cell preventing nutrient transport was also demonstrated [147]. In addition, antibacterial efficacy could be related to ALG chelation capacity responsible for modulating the production of toxins, microbial growth, and factors crucial for microorganisms stability. Bacteriostatic activity of ALG was proved against a wide variety of species, including Pseudomonas, Escherichia, Proteus, and Acinetobacter [42, 43]. Nonetheless, it ought to be point out that the antimicrobial activity of ALG differs substantially according to a number of factors, namely, molecular weight, M/G-block ratio, modification of their structure, environmental pH, and the state of applied formulation [145].

Sulfated polysaccharides and alginic acid-containing fractions extracted from algae were found to exert antiviral efficacy against a number of viruses families, including Flaviviridae, Togaviridae, Rhabdoviridae, and Herpesviridae and might be helpful in treatment of virus infections [146, 149151]. The mode of action may be related to the strong anionic charge of sulfated ALG capable of interacting with the positively charged host cell and, as a result, virus contact with the host cell is prevented and the viral material could not enter in the cells [61, 152154]. In contrary, Meiyu et al. indicated that virus penetration was inhibited by physical barrier created by ALG around the cell [154]. Furthermore, studies performed by Son et al. revealed that ALG with high M-block content possessed immunostimulating properties by activating macrophages responsible for excreting cytokines and cytotoxic factors [155].

Haemostatic efficacy of calcium alginate through platelets activation and thrombin generation was also displayed [156159] enabling polymer application in wound dressings [3033]. Furthermore, sulfated ALG derivative propylene glycol alginate sodium sulfate (PSS) is the first oral heparinoid approved by Chinese Food and Drug Administration and has been used as an anticoagulant drug for over 30 years [160].

Sodium alginate oligosaccharides have been reported to lower blood pressure [64]. The hypotensive mechanism appeared to be associated with calcium antagonist activity, especially toward voltage-operated calcium channels [65]. Sodium alginate oligosaccharides in dose 60 mg/day were found to decrease blood pressure and to eliminate hypertension after 14 days of treatment, whereas Moriya et al. displayed polymers facility to prevent early-stage of kidney injury by decreasing the rate of glomerular filtration [66]. In addition, alginate potassium might be considered as promising agent for preventing cardiovascular complications associated with hypertension, including cardiac, renal hypertrophy in the risk of stroke occurrence [161].

Antioxidant and anti-inflammatory activity of alginate oligosaccharides was also observed. Alginate oligosaccharides were found to attenuate the production of nitric oxide, reactive oxygen species (ROS), prostaglandin E2, and cyclooxygenase COX-2 [57, 162166]. Yamamoto et al. demonstrated that the mechanism underlying antioxidant effect of high mannuronic alginate was based on stimulating monocytes to secrete anti-inflammatory cytokines [164]. Additionally, because of chelating capacity, ALG are capable of binding toxins and heavy metals in the intestine, protecting cells from the carcinogenesis process [57, 60, 163166]. Furthermore, Jeong et al. indicated that alginic acid exerted antianaphylactic activity relating to inhibition of histamine release from mast cells followed with downregulation of histidine decarboxylase and proinflammatory cytokines expression [167]. Moreover, studies performed by Uno et al. showed that alginic acid reduced IgE production in the serum of mice immunized with β lactoglobulin [168]. Additionally, alginic acid at concentration of 0.01 µg/ml was found to reduce histamine release from rat peritoneal mast cells up to 60% [167].

5. Future Perspectives

5.1. ALG-Based Three-Dimensional (3D) Cell Culture Systems

3D culture systems, macroporous structures prepared from using natural, synthetic polymers or their composites, with ability to reflect the native extracellular matrix and natural physiological conditions have been regarded as advanced technology for complex cellular physiology investigations, drug evaluation, and tissue engineering [169171]. Among natural polymers, ALG, with regard to gel formation ability, mechanical strength, and interactions with cell via bioadhesive bonds, are considered to be promising material for cell and tissue culture and have been employed as 3D systems [89]. 3D material based on ionically gelled and dried ALG macroporous scaffolds creates favorable conditions for cellular attachment, proliferation, and differentiation. ALG scaffolds are able to turn into hydrogels upon rehydration following cell seeding. At present, two ALG-based 3D products for cell culture AlgiMatrix® (Thermo Fisher Scientific/Life Technologies, USA) and NovaMatrix® 3D (NovaMatrix, Norway) are commercially available in different formats of standard cell culture well plates [172, 173]. AlgiMatrix is a lyophilized sponge prepared of pharmaceutical-grade ALG extracted from brown seaweed. After application of the cell suspension on the top surface of porous ALG-platform, the lyophilisate becomes hydrated and entraps cells inside its porous structure [174]. Unopened product is stable at room temperature up to 12 months. In contrary, NovaMatrix 3D comprises sterile ALG foam structure, a source of gel forming ions to initiate polymer gelation, and a vial of lyophilized ALG to be dissolved in a culture medium. Once the pores are filled with the ALG solution, in situ hydrogel is formed which enables fast and gentle cell immobilization under physiological conditions [170, 173].

5.2. Cell-Based Microparticles for Therapeutic Applications

Immobilization of living cells or cell inducing factors in ALG matrix is commonly used technique in tissue and cartilage engineering. Over the last ten years, an advanced research has been conducted on the development of cell transplantation therapy in long-term diabetes and neurodegenerative diseases treatment with using ALG-encapsulation technology Immupel™ (LCT, Living Cell Technologies Limited, Australia). This selectively permeable system with ability to protect the encapsulated living cells from host immune system manages them to function and differentiate accurately [175177]. Currently, two ALG-based products, DIABECELL® and NTCELL®, are in advanced stage of clinical investigations.

DIABECELL implant consists of microencapsulated neonatal porcine islets capable of secreting insulin. The single system is designed to be delivered into the patients abdomen during laparoscopy procedure. Each multilayer microcapsule comprises the inner core of ALG (M/G ratio 60 : 40) cross-linked with calcium chloride and coated with poly-L-ornithine- (PLO-) polycationic polymer responsible for strengthening the capsule wall. To reduce the risk of immunogenicity arisen from the presence of PLO, the additional outer layer prepared of ALG is present [178, 179]. Recently additional modification of microcapsules shell by cross-linking the PLO surface with genipin has been employed in order to improve microcapsules biocompatibility. The clinical data displayed a statistically significant efficacy of DIABECELL in reduction of hypoglycemic episodes in patients with type 1 diabetes after transplantation [179]. Another example of porcine pancreatic islet cells encapsulation is monolayer cellular device (MCD) technology. A single capsule contains collagen matrix base and monolayer of porcine islet cells (monolayer allows for a faster kinetic diffusion relative to the cluster of islands) and then coated by gelled layer built of 3% (w/v) ALG. The capsules are formatted to a 1–32 cm sheet for subcutaneous implantation. The MCD was histologically examined after a resection. Surrounded tissues graft fibrosis or ALG degradation has not been observed. In comparison to nonencapsulated porcine islets, less level of lymphocytes and macrophages has been noted [180, 181].

NTCELL with choroid plexus cells encapsulated within Immupel platform has been displayed to regenerate damaged tissue and significantly restore function in humans with Parkinson’s disease. Following implantation into an impaired site within the brain of model animals, NTCELL was found to promote the production of cerebrospinal fluid as well as nerve growth factors. In addition to Parkinson’s disease, the product may have the potential to be utilized in a number of other neurodegenerative disorders, including Huntington’s, Alzheimer’s or motor neuronal diseases [182, 183].

5.3. Biological Activity of ALG Oligosaccharides

In recent years, ALG oligosaccharides, low molecular polymer fragments obtained by enzymatic depolymerization or acid hydrolysis at elevated temperatures, have received much attention because of their unique opportunity for combination treatment in which the polymer acts as the drug vehicle and concomitantly as an active part of the therapy [116]. Examples of ALG oligosaccharides with biological activity and pharmaceutical application were presented in Table 5.

CompoundMechanism of actionBiological activity and pharmaceutical application

(ALG oligosaccharide)
Regulation of mucus viscosity by induction alterations in mucin surface charge, formation porosity of the mucin networks in cystic fibrosis sputum;
eradication bacterial and fungal lung infections by modification of biofilm structure together with growth inhibition, improvement the efficiency of conventional antibiotics against multidrug resistant bacteria or fungi
Cystic fibrosis, treatment of chronic obstructive pulmonary disease (COPD),
improvement of antibacterial and antifungal therapy, antifungal activity
Khan et al. [42]
Pritchard et al. [43]
Powell et al. [44]
Heparinoid 911 (sulfated
high mannuronic and guluronic oligosaccharides)
Interaction with glycoproteins present on the cell surface, which leads to the counteracting HIV-virus, prevention of viral adsorption and inhibition of viral reverse transcriptase;
inhibition of DNA polymerase of hepatitis B virus
hepatitis B virus
Xin et al. [45]
Xin et al. [46]
Jiang et al. [47]
Wu et al. [48]
ALG oligosaccharides;
Inhibition effect on neuroinflammation, promotion effect on microglial phagocytosis, protection neurons from cell death by blocking oxidative stress, inhibition of production of nitric oxide and prostaglandin E2, expression of inducible nitric oxide synthase and cyclooxygenase 2, secretion of proinflammatory cytokines, promotion of the phagocytosis of amyloid β protein through its interaction with toll-like receptor 4 (TLR4) in microglia
Alzheimer’s disease and neurodegenerative diseasesTusi et al. [49]
Zhou et al. [50]
Manigandan et al. [51]
Hu et al. [52]
Wang et al. [53]
Propylene glycol alginate sodium sulfate oligosaccharides (PSS)Inhibition of thrombin by interfering with the coagulation cascade, prolongation of the activated partial thromboplastin time, clotting time and reduction platelet aggregation
Anticoagulant and antithrombotic activity, blood viscosity reductionRonghua et al. [54]
Xin et al. [55]
Guluronate oligosaccharideReduction of the production of nitric oxide, prostaglandin E2, reactive oxygen species, the expression of inducible nitric oxide synthase and cyclooxygenase 2, secretion of proinflammatory cytokines IL-1 and IL-6, reduction of the inflammatory responses through blocking the activation of nuclear factor NF-κB and mitogen-activated protein kinases, inhibition lipid peroxidation
Antioxidant and anti-inflammatory activity,
protection cells from the carcinogenesis process
Falkeborg et al. [56]
Zhou et al [57]
An et al. [58]
Ji et al. [59]
Hu et al. [60]
Unsaturated guluronate oligosaccharideDose and time depend on induction of production of nitric oxide, inducible nitric oxide synthase, reactive oxygen species and TNF-α, induction of macrophage to release nuclear factor NF-κB and mitogen-activated protein kinase signaling pathways
Immunomodulatory activity
Xu et al. [61]
Xu et al. [62]
ALG oligosaccharidesStimulation cecal and fecal microflora
Probiotic and prebiotic activityWang et al. [63]
Sodium alginate oligosaccharides
(including unsaturated 3α-L-guluronate
and/or β-D-mannuronate)
Hypothesis mechanism involves blood pressure reduction related to direct action on vascular vessels, by effect on the adrenergic nervous system or endothelial cell functionHypertensionTerakado et al. [64]
Chaki et al. [65]
Moriya et al. [66]

OligoG®, the highly purified oligomer with a high content of G-blocks and a relatively narrow molecular weight distribution, represents a novel therapeutic approach for treatment of microbial infections [184]. The unique mode of OligoG action is related to mucolytic activity and modification of biofilm formed by bacteria during colonization process. OligoG (at concentration of 10%) is able to alter the biofilm surface charge and porosity, weakening its growth and as a result to damage pathogens cell membranes. OligoG was demonstrated to increase the efficiency of conventional antibiotics against several resistant pathogens, including Pseudomonas, Acinetobacter, and Burkholderia sp. [184, 185]. In addition, Tøndervik et al. indicated that OligoG improved antifungal activity of commonly used polyenes, azoles, and allylamines against Aspergillus and Candida strains [186]. OligoG is currently being tested as novel inhaled polymer therapy for the treatment of chronic respiratory disease. The advantage of OligoG is its suitability for pulmonary administration after simple dissolution in isotonic solvents followed with effective lung deposition and resistance to enzymatic degradation [43].

It should be noted that ALG oligosaccharides might be also considered as promising probiotic and prebiotic agents due to their beneficial effect on promoting the growth of Bifidobacterium sp. with simultaneous inhibition of Salmonella enteritidis colonization in the large intestine [187]. The influence on the balance of commensal bacteria could be attributed to immunostimulatory activity of oligosaccharides through ability to upregulate the production of anti-inflammatory factors [61, 62].

Additionally, considerable research effort has been made to explore the usability of heparinoid ALG derivatives to support HIV treatment. At present, drug 911, sulfated high mannuronic and guluronic heterogeneous fragments of ALG, belonging to a group of heparinoid polysaccharides, is in advanced phase of clinical investigations in China as anti-AIDS drug [4548]. Heparinoid 911 possesses an average molecular weight of 10 kDa and 1.5 sulfates and 1.0 carboxyl groups per sugar residue [48]. Heparinoid 911 was demonstrated to interact with the positively charged regions of glycoproteins present on the cell surface, leading to the shielding effect on these regions, thus counteracting HIV-virus binding to the cell surface [45, 46]. The unique mode of 911 action was found to be related to the inhibition of viral reverse transcriptase and prevention of viral adsorption. Furthermore, a significant inhibitory effect on DNA polymerase of hepatitis B virus was also reported which gives the opportunity to apply 911 in hepatitis B treatment [47].

6. Conclusions

Owing to unique properties, swelling capacity, mucoadhesiveness, and ability of sol/gel transition ALG have gained a preferential place in the development of advanced drug delivery systems. These natural, multifunctional polymers are widely studied in the design of microparticulate systems for controlled release, targeted drug delivery, and biomedical application (as matrix for three-dimensional tissue cultures, adjuvants of antibiotics, and antiviral agents or in cell transplantation in diabetes and neurodegenerative diseases treatment). Additionally, highly absorbent ALG-based hydrogels with mechanical stability and viscoelastic properties are applied as wound dressing. This paper also describes ALG chemical modifications, ALG biological activity, and application in pharmaceutical products.

Competing Interests

The authors declare no conflict of interests.


This study was supported by Medical University of Białystok Grant (no. N/ST/MN/16/001/2215).


  1. M. A. Repka and A. Singh, “Alginic acid,” in Handbook of Pharmaceutical Excipients, pp. 20–22, Pharmaceutical Press, London, UK, 6th edition, 2009. View at: Google Scholar
  2. K. N. Sachan, S. Pushkar, A. Jha, and A. Bhattcharya, “Sodium alginate: the wonder polymer for controlled drug delivery,” Journal of Pharmacy Research, vol. 2, no. 8, pp. 1191–1199, 2009. View at: Google Scholar
  3. U. Remminghorst and B. H. A. Rehm, “Bacterial alginates: from biosynthesis to applications,” Biotechnology Letters, vol. 28, no. 21, pp. 1701–1712, 2006. View at: Publisher Site | Google Scholar
  4. C. G. Cable, “Sodium alginate,” in Handbook of Pharmaceutical Excipients, pp. 622–624, Pharmaceutical Press, London, UK, 6th edition, 2009. View at: Google Scholar
  5. The United States Pharmacopeia, “The United States pharmacopeial convention,” USP 34-NF 29, The United States Pharmacopeial Convention, Rockville, Md, USA, 2011. View at: Google Scholar
  6. Council of Europe, The European Pharmacopoeia 7.0, Council of Europe, Strasbourg, France, 2011.
  7. S. A. Shah and D. Thassu, “Ammonium alginate,” in Handbook of Pharmaceutical Excipients, p. 41, Pharmaceutical Press, London, UK, 6th edition, 2009. View at: Google Scholar
  8. C. G. Gable, “Calcium alginate,” in Handbook of Pharmaceutical Excipients, pp. 83–85, Pharmaceutical Press, London, UK, 6th edition, 2009. View at: Google Scholar
  9. R. G. Nause, R. D. Reddy, and J. L. P. Soh, “Propylene glycol alginate,” in Handbook of Pharmaceutical Excipients, pp. 594–595, Pharmaceutical Press, London, UK, 6th edition, 2009. View at: Google Scholar
  10. B. Wright, P. A. De Bank, K. A. Luetchford, F. R. Acosta, and C. J. Connon, “Oxidized alginate hydrogels as niche environments for corneal epithelial cells,” Journal of Biomedical Materials Research—Part A, vol. 102, no. 10, pp. 3393–3400, 2014. View at: Publisher Site | Google Scholar
  11. S. Maiti, K. Singha, S. Ray, P. Dey, and B. Sa, “Adipic acid dihydrazide treated partially oxidized alginate beads for sustained oral delivery of flurbiprofen,” Pharmaceutical Development and Technology, vol. 14, no. 5, pp. 461–470, 2009. View at: Publisher Site | Google Scholar
  12. R. Mahou, R. R. H. Meier, L. H. Bühler, and C. Wandrey, “Alginate-poly(ethylene glycol) hybrid microspheres for primary cell microencapsulation,” Materials, vol. 7, no. 1, pp. 275–286, 2014. View at: Publisher Site | Google Scholar
  13. Ø. Arlov, G. Skjåk-Bræk, and A. M. Rokstad, “Sulfated alginate microspheres associate with factor H and dampen the inflammatory cytokine response,” Acta Biomaterialia, vol. 42, pp. 180–188, 2016. View at: Publisher Site | Google Scholar
  14. R. J. Coleman, G. Lawrie, L. K. Lambert, M. Whittaker, K. S. Jack, and L. Grndahl, “Phosphorylation of alginate: synthesis, characterization, and evaluation of in vitro mineralization capacity,” Biomacromolecules, vol. 12, no. 4, pp. 889–897, 2011. View at: Publisher Site | Google Scholar
  15. R. Tripathi and B. Mishra, “Development and evaluation of sodium alginate-polyacrylamide graft-co-polymer-based stomach targeted hydrogels of famotidine,” AAPS PharmSciTech, vol. 13, no. 4, pp. 1091–1102, 2012. View at: Publisher Site | Google Scholar
  16. A. Chang, “pH-sensitive starch-g-poly(acrylic acid)/sodium alginate hydrogels for controlled release of diclofenac sodium,” Iranian Polymer Journal, vol. 24, no. 2, pp. 161–169, 2015. View at: Publisher Site | Google Scholar
  17. X. Wang, T. Hao, J. Qu, C. Wang, and H. Chen, “Synthesis of thermal polymerizable alginate-GMA hydrogel for cell encapsulation,” Journal of Nanomaterials, vol. 2015, Article ID 970619, 8 pages, 2015. View at: Publisher Site | Google Scholar
  18. M. Tian, B. Han, H. Tan, and C. You, “Preparation and characterization of galactosylated alginate-chitosan oligomer microcapsule for hepatocytes microencapsulation,” Carbohydrate Polymers, vol. 112, pp. 502–511, 2014. View at: Publisher Site | Google Scholar
  19. W. Pluemsab, Y. Fukazawa, T. Furuike, Y. Nodasaka, and N. Sakairi, “Cyclodextrin-linked alginate beads as supporting materials for Sphingomonas cloacae, a nonylphenol degrading bacteria,” Bioresource Technology, vol. 98, no. 11, pp. 2076–2081, 2007. View at: Publisher Site | Google Scholar
  20. H. Izawa, K. Kawakami, M. Sumita, Y. Tateyama, J. P. Hill, and K. Ariga, “β-Cyclodextrin-crosslinked alginate gel for patient-controlled drug delivery systems: regulation of host-guest interactions with mechanical stimuli,” Journal of Materials Chemistry B, vol. 1, no. 16, pp. 2155–2161, 2013. View at: Publisher Site | Google Scholar
  21. R. Hurteaux, F. Edwards-Lévy, D. Laurent-Maquin, and M.-C. Lévy, “Coating alginate microspheres with a serum albumin-alginate membrane: application to the encapsulation of a peptide,” European Journal of Pharmaceutical Sciences, vol. 24, no. 2-3, pp. 187–197, 2005. View at: Publisher Site | Google Scholar
  22. Clinical Trials (Internet), U.S. National Institutes of Health,
  23. D. Ummarino, E. Miele, M. Martinelli et al., “Effect of magnesium alginate plus simethicone on gastroesophageal reflux in infants,” Journal of Pediatric Gastroenterology and Nutrition, vol. 60, no. 2, pp. 230–235, 2015. View at: Publisher Site | Google Scholar
  24. Md. Jakaria, R. Zaman, M. Parvez et al., “Comparative study among the different formulation of antacid tablets by using acid-base neutralization reaction,” Global Journal of Pharmacology, vol. 9, no. 3, pp. 278–281, 2015. View at: Publisher Site | Google Scholar
  25. A. De Ruigh, S. Roman, J. Chen, J. E. Pandolfino, and P. J. Kahrilas, “Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study,” Alimentary Pharmacology and Therapeutics, vol. 40, no. 5, pp. 531–537, 2014. View at: Publisher Site | Google Scholar
  26. E. Thomas, A. Wade, G. Crawford, B. Jenner, N. Levinson, and J. Wilkinson, “Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate–antacid (Gaviscon Double Action)—a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease,” Alimentary Pharmacology and Therapeutics, vol. 39, no. 6, pp. 595–602, 2014. View at: Publisher Site | Google Scholar
  27. Z. M. Rashaan, P. Krijnen, M. E. van den Akker- van Marle et al., “Clinical effectiveness, quality of life and cost-effectiveness of Flaminal® versus Flamazine® in the treatment of partial thickness burns: study protocol for a randomized controlled trial,” Trials, vol. 17, article122, 9 pages, 2016. View at: Publisher Site | Google Scholar
  28. E. Caló and V. V. Khutoryanskiy, “Biomedical applications of hydrogels: a review of patents and commercial products,” European Polymer Journal, vol. 65, pp. 252–267, 2015. View at: Publisher Site | Google Scholar
  29. C. Sussman and B. Bates-Jensen, “Management of the wound environment with dressings and topical agents,” in Wound Care a Collaborative Practice Manual for Health Professionals, p. 254, Lippincott Williams & Wilkins, 3rd edition, 2007. View at: Google Scholar
  30. S. Carella, M. Maruccia, P. Fino, and M. G. Onesti, “An atypical case of Henoch-Shönlein purpura in a young patient: treatment of the skin lesions with hyaluronic acid-based dressings,” In Vivo, vol. 27, no. 1, pp. 147–151, 2013. View at: Google Scholar
  31. E. Ausili, V. Paolucci, S. Triarico et al., “Treatment of pressure sores in spina bifida patients with calcium alginate and foam dressings,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 12, pp. 1642–1647, 2013. View at: Google Scholar
  32. S. Bale, N. Baker, H. Crook, A. Rayman, G. Rayman, and K. G. Harding, “Exploring the use of an alginate dressing for diabetic foot ulcers,” Journal of Wound Care, vol. 10, no. 3, pp. 81–84, 2001. View at: Publisher Site | Google Scholar
  33. M. Porter and J. Kelly, “Pressure ulcer treatment in a patient with spina bifida,” Nursing Standard, vol. 28, no. 35, pp. 60–69, 2014. View at: Publisher Site | Google Scholar
  34. E. J. Sohn, H. B. Ahn, M. S. Roh, W. Y. Ryu, and Y. H. Kwon, “Efficacy of temperature-sensitive guardix-sg for adhesiolysis in experimentally induced eyelid adhesion in rabbits,” Ophthalmic Plastic and Reconstructive Surgery, vol. 29, no. 6, pp. 458–463, 2013. View at: Publisher Site | Google Scholar
  35. S. O. Park, J. Han, K. W. Minn, and U. S. Jin, “Prevention of capsular contracture with Guardix-SG® after silicone implant insertion,” Aesthetic Plastic Surgery, vol. 37, no. 3, pp. 543–548, 2013. View at: Publisher Site | Google Scholar
  36. L. Abramowitz, G. H. Weyandt, B. Havlickova et al., “The diagnosis and management of haemorrhoidal disease from a global perspective,” Alimentary Pharmacology and Therapeutics, vol. 31, supplement 1, pp. 1–58, 2010. View at: Google Scholar
  37. E. Gruskin, B. A. Doll, F. W. Futrell, J. P. Schmitz, and J. O. Hollinger, “Demineralized bone matrix in bone repair: history and use,” Advanced Drug Delivery Reviews, vol. 64, no. 12, pp. 1063–1077, 2012. View at: Publisher Site | Google Scholar
  38. E. Al Machot, T. Hoffmann, K. Lorenz, I. Khalili, and B. Noack, “Clinical outcomes after treatment of periodontal intrabony defects with nanocrystalline hydroxyapatite (Ostim) or enamel matrix derivatives (Emdogain): a randomized controlled clinical trial,” BioMed Research International, vol. 2014, Article ID 786353, 9 pages, 2014. View at: Publisher Site | Google Scholar
  39. X. Z. Yan, F. Rathe, C. Gilissen et al., “The effect of enamel matrix derivative (Emdogain®) on gene expression profiles of human primary alveolar bone cells,” Journal of Tissue Engineering and Regenerative Medicine, vol. 8, no. 6, pp. 463–472, 2014. View at: Publisher Site | Google Scholar
  40. A. Sculean, T. M. Auschill, N. Donos, M. Brecx, and N. B. Arweiler, “Effect of an enamel matrix protein derivative (Emdogain) on ex vivo dental plaque vitality,” Journal of Clinical Periodontology, vol. 28, no. 11, pp. 1074–1078, 2001. View at: Publisher Site | Google Scholar
  41. A. Barzegari and A. A. Saei, “An update to space biomedical research: tissue engineering in microgravity bioreactors,” BioImpacts, vol. 2, no. 1, pp. 23–32, 2012. View at: Publisher Site | Google Scholar
  42. S. Khan, A. Tøndervik, H. Sletta et al., “Overcoming drug resistance with alginate oligosaccharides able to potentiate the action of selected antibiotics,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 10, pp. 5134–5141, 2012. View at: Publisher Site | Google Scholar
  43. M. F. Pritchard, L. C. Powell, G. E. Menzies et al., “A new class of safe oligosaccharide polymer therapy to modify the mucus barrier of chronic respiratory disease,” Molecular Pharmaceutics, vol. 13, no. 3, pp. 863–872, 2016. View at: Publisher Site | Google Scholar
  44. L. C. Powell, M. F. Pritchard, C. Emanuel et al., “A nanoscale characterization of the interaction of a novel alginate oligomer with the cell surface and motility of Pseudomonas aeruginosa,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 3, pp. 483–492, 2014. View at: Publisher Site | Google Scholar
  45. X. L. Xin, M. Y. Geng, H. S. Guan, and Z. L. Li, “Study on the mechanism of inhibitory action of 911 on replication of HIV-1 in vitro,” Chinese Journal of Marine Drugs, vol. 19, no. 4, pp. 15–18, 2000. View at: Google Scholar
  46. X. L. Xin, H. Ding, M. Y. Geng, P. F. Liang, Y. X. Li, and H. S. Guan, “Studies of the anti-AIDS effects of marine polysaccharide drug 911 and its related mechanisms of action,” Chinese Journal of Marine Drugs, vol. 19, no. 6, pp. 4–8, 2000. View at: Google Scholar
  47. B. F. Jiang, X. F. Xu, L. Li, and W. Yuan, “Study on ‘911’ anti-HBV effect in HepG2.2.15 cells culture,” Modern Preventive Medicine, no. 30, pp. 517–518, 2003. View at: Google Scholar
  48. Y.-L. Wu, J. Ai, J.-M. Zhao et al., “Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad,” Acta Pharmacologica Sinica, vol. 32, no. 5, pp. 647–654, 2011. View at: Publisher Site | Google Scholar
  49. S. K. Tusi, L. Khalaj, G. Ashabi, M. Kiaei, and F. Khodagholi, “Alginate oligosaccharide protects against endoplasmic reticulum- and mitochondrial-mediated apoptotic cell death and oxidative stress,” Biomaterials, vol. 32, no. 23, pp. 5438–5458, 2011. View at: Publisher Site | Google Scholar
  50. R. Zhou, X.-Y. Shi, D.-C. Bi, W.-S. Fang, G.-B. Wei, and X. Xu, “Alginate-derived oligosaccharide inhibits neuroinflammation and promotes microglial phagocytosis of β-amyloid,” Marine Drugs, vol. 13, no. 9, pp. 5828–5846, 2015. View at: Publisher Site | Google Scholar
  51. V. Manigandan, R. Karthik, and R. Saravanan, “Marine carbohydrate based therapeutics for Alzheimer disease—mini review,” Journal of Neurology and Neuroscience, In press. View at: Google Scholar
  52. J. Hu, M. Geng, J. Li et al., “Acidic oligosaccharide sugar chain, a marine-derived acidic oligosaccharide, inhibits the cytotoxicity and aggregation of amyloid beta protein,” Journal of Pharmacological Sciences, vol. 95, no. 2, pp. 248–255, 2004. View at: Publisher Site | Google Scholar
  53. S. Wang, J. Li, W. Xia, and M. Geng, “A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by β-amyloid-induced astrocyte activation in vitro,” Neurological Research, vol. 29, no. 1, pp. 96–102, 2007. View at: Publisher Site | Google Scholar
  54. H. Ronghua, D. Yumin, and Y. Jianhong, “Preparation and in vitro anticoagulant activities of alginate sulfate and its quaterized derivatives,” Carbohydrate Polymers, vol. 52, no. 1, pp. 19–24, 2003. View at: Publisher Site | Google Scholar
  55. M. Xin, L. Ren, Y. Sun et al., “Anticoagulant and antithrombotic activities of low-molecular-weight propylene glycol alginate sodium sulfate (PSS),” European Journal of Medicinal Chemistry, vol. 114, pp. 33–40, 2016. View at: Publisher Site | Google Scholar
  56. M. Falkeborg, L.-Z. Cheong, C. Gianfico et al., “Alginate oligosaccharides: enzymatic preparation and antioxidant property evaluation,” Food Chemistry, vol. 164, pp. 185–194, 2014. View at: Publisher Site | Google Scholar
  57. R. Zhou, X. Shi, Y. Gao, N. Cai, Z. Jiang, and X. Xu, “Anti-inflammatory activity of guluronate oligosaccharides obtained by oxidative degradation from alginate in lipopolysaccharide-activated murine macrophage RAW 264.7 cells,” Journal of Agricultural and Food Chemistry, vol. 63, no. 1, pp. 160–168, 2015. View at: Publisher Site | Google Scholar
  58. Q.-D. An, G.-L. Zhang, H.-T. Wu et al., “Alginate-deriving oligosaccharide production by alginase from newly isolated Flavobacterium sp. LXA and its potential application in protection against pathogens,” Journal of Applied Microbiology, vol. 106, no. 1, pp. 161–170, 2009. View at: Publisher Site | Google Scholar
  59. J. Ji, L. Wang, H. Wu, and H. Luan, “Bio-function summary of marine oligosaccharides,” International Journal of Biology, vol. 3, no. 1, pp. 74–86, 2011. View at: Publisher Site | Google Scholar
  60. X. Hu, X. Jiang, H. Hwang, S. Liu, and H. Guan, “Antitumour activities of alginate-derived oligosaccharides and their sulphated substitution derivatives,” European Journal of Phycology, vol. 39, no. 1, pp. 67–71, 2004. View at: Publisher Site | Google Scholar
  61. X. Xu, X. Wu, Q. Wang et al., “Immunomodulatory effects of alginate oligosaccharides on murine macrophage RAW264.7 cells and their structure-activity relationships,” Journal of Agricultural and Food Chemistry, vol. 62, no. 14, pp. 3168–3176, 2014. View at: Publisher Site | Google Scholar
  62. X. Xu, D. Bi, X. Wu et al., “Unsaturated guluronate oligosaccharide enhances the antibacterial activities of macrophages,” FASEB Journal, vol. 28, no. 6, pp. 2645–2654, 2014. View at: Publisher Site | Google Scholar
  63. Y. Wang, F. Han, B. Hu, J. Li, and W. Yu, “In vivo prebiotic properties of alginate oligosaccharides prepared through enzymatic hydrolysis of alginate,” Nutrition Research, vol. 26, no. 11, pp. 597–603, 2006. View at: Publisher Site | Google Scholar
  64. S. Terakado, M. Ueno, Y. Tamura et al., “Sodium alginate oligosaccharides attenuate hypertension and associated kidney damage in Dahl salt-sensitive rats fed a high-salt diet,” Clinical and Experimental Hypertension, vol. 34, no. 2, pp. 99–106, 2012. View at: Publisher Site | Google Scholar
  65. T. Chaki, N. Kajimoto, H. Ogawa, T. Baba, and N. Hiura, “Metabolism and calcium antagonism of sodium alginate oligosaccharides,” Bioscience, Biotechnology and Biochemistry, vol. 71, no. 8, pp. 1819–1825, 2007. View at: Publisher Site | Google Scholar
  66. C. Moriya, Y. Shida, Y. Yamane et al., “Subcutaneous administration of sodium alginate oligosaccharides prevents salt-induced hypertension in dahl salt-sensitive rats,” Clinical and Experimental Hypertension, vol. 35, no. 8, pp. 607–613, 2013. View at: Publisher Site | Google Scholar
  67. C. K. Kuo and P. X. Ma, “Ionically crosslinked alginate hydrogels as scaffolds for tissue engineering: part 1. Structure, gelation rate and mechanical properties,” Biomaterials, vol. 22, no. 6, pp. 511–521, 2001. View at: Publisher Site | Google Scholar
  68. K. I. Draget, G. Skjåk Bræk, and O. Smidsrød, “Alginic acid gels: the effect of alginate chemical composition and molecular weight,” Carbohydrate Polymers, vol. 25, no. 1, pp. 31–38, 1994. View at: Publisher Site | Google Scholar
  69. D. Brault, A. Heyraud, V. Lognone, and M. Roussel, “Methods for obtaining oligomannuronates and guluronates, products obtained and use thereof,” Patent WO03099870, 2003. View at: Google Scholar
  70. T. Shimokawa, S. Yoshida, T. Takeuchi, K. Murata, T. Ishii, and I. Kusakabe, “Preparation of two series of oligo-guluronic acids from sodium alginate by acid hydrolysis and enzymatic degradation,” Bioscience, Biotechnology and Biochemistry, vol. 60, no. 9, pp. 1532–1534, 1996. View at: Publisher Site | Google Scholar
  71. K. I. Draget, M. K. Simensen, E. Onsøyen, and O. Smidsrød, “Gel strength of Ca-limited alginate gels made in situ,” Hydrobiologia, vol. 260-261, no. 1, pp. 563–565, 1993. View at: Publisher Site | Google Scholar
  72. S. Fu, A. Thacker, D. M. Sperger et al., “Relevance of rheological properties of sodium alginate in solution to calcium alginate gel properties,” AAPS PharmSciTech, vol. 12, no. 2, pp. 453–460, 2011. View at: Publisher Site | Google Scholar
  73. B. B. Crow and K. D. Nelson, “Release of bovine serum albumin from a hydrogel-cored biodegradable polymer fiber,” Biopolymers, vol. 81, no. 6, pp. 419–427, 2006. View at: Publisher Site | Google Scholar
  74. A. D. Augst, H. J. Kong, and D. J. Mooney, “Alginate hydrogels as biomaterials,” Macromolecular Bioscience, vol. 6, no. 8, pp. 623–633, 2006. View at: Publisher Site | Google Scholar
  75. Y. Zhao, W. Shen, Z. Chen, and T. Wu, “Freeze-thaw induced gelation of alginates,” Carbohydrate Polymers, vol. 148, pp. 45–51, 2016. View at: Publisher Site | Google Scholar
  76. W. R. Gombotz and S. F. Wee, “Protein release from alginate matrices,” Advanced Drug Delivery Reviews, vol. 31, no. 3, pp. 267–285, 1998. View at: Publisher Site | Google Scholar
  77. T. E. Jørgensen, M. Sletmoen, K. I. Draget, and B. T. Stokke, “Influence of oligoguluronates on alginate gelation, kinetics, and polymer organization,” Biomacromolecules, vol. 8, no. 8, pp. 2388–2397, 2007. View at: Publisher Site | Google Scholar
  78. B. Niekraszewicz and A. Niekraszewicz, “The structure of alginate, chitin and chitosan fibres,” in Handbook of Textile Fibre Structure, pp. 266–304, Woodhead Publishing Limited, Cambridge, UK, 2009. View at: Google Scholar
  79. E. A. Wahl, F. A. Fierro, T. R. Peavy et al., “In vitro evaluation of scaffolds for the delivery of mesenchymal stem cells to wounds,” BioMed Research International, vol. 2015, Article ID 108571, 14 pages, 2015. View at: Publisher Site | Google Scholar
  80. J. W. Doyle, T. P. Roth, R. M. Smith, Y.-Q. Li, and R. M. Dunn, “Effect of calcium alginate on cellular wound healing processes modeled in vitro,” Journal of Biomedical Materials Research, vol. 32, no. 4, pp. 561–568, 1996. View at: Publisher Site | Google Scholar
  81. S. Thomas, “Alginate dressings in surgery and wound management—Part 1,” Journal of Wound Care, vol. 9, no. 2, pp. 56–60, 2000. View at: Publisher Site | Google Scholar
  82. H. Almeida, M. H. Amaral, P. Lobão, and J. M. S. Lobo, “In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations,” Drug Discovery Today, vol. 19, no. 4, pp. 400–412, 2014. View at: Publisher Site | Google Scholar
  83. A. Michael Rajesh, S. A. Bhatt, H. Brahmbhatt, P. S. Anand, and K. M. Popat, “Taste masking of ciprofloxacin by ion-exchange resin and sustain release at gastric-intestinal through interpenetrating polymer network,” Asian Journal of Pharmaceutical Sciences, vol. 10, no. 4, pp. 331–340, 2014. View at: Publisher Site | Google Scholar
  84. M. Jelvehgari, L. Barghi, and F. Barghi, “Preparation of chlorpheniramine maleate-loaded alginate/chitosan particulate systems by the ionic gelation method for taste masking,” Jundishapur Journal of Natural Pharmaceutical Products, vol. 9, no. 1, pp. 39–48, 2014. View at: Publisher Site | Google Scholar
  85. P. Ciosek, M. Wesoły, M. Zabadaj et al., “Towards flow-through/flow injection electronic tongue for the analysis of pharmaceuticals,” Sensors and Actuators, B: Chemical, vol. 207, pp. 1087–1094, 2015. View at: Publisher Site | Google Scholar
  86. K. Y. Lee and D. J. Mooney, “Alginate: properties and biomedical applications,” Progress in Polymer Science, vol. 37, no. 1, pp. 106–126, 2012. View at: Publisher Site | Google Scholar
  87. H. H. Tønnesen and J. Karlsen, “Alginate in drug delivery systems,” Drug Development and Industrial Pharmacy, vol. 28, no. 6, pp. 621–630, 2002. View at: Publisher Site | Google Scholar
  88. A. L. Ching, C. V. Liew, L. W. Chan, and P. W. S. Heng, “Modifying matrix micro-environmental pH to achieve sustained drug release from highly laminating alginate matrices,” European Journal of Pharmaceutical Sciences, vol. 33, no. 4-5, pp. 361–370, 2008. View at: Publisher Site | Google Scholar
  89. J. Sun and H. Tan, “Alginate-based biomaterials for regenerative medicine applications,” Materials, vol. 6, no. 4, pp. 1285–1309, 2013. View at: Publisher Site | Google Scholar
  90. E. García-Gareta, N. Ravindran, V. Sharma, S. Samizadeh, and J. F. Dye, “A novel multiparameter in vitro model of three-dimensional cell ingress into scaffolds for dermal reconstruction to predict in vivo outcome,” BioResearch Open Access, vol. 2, no. 6, pp. 412–420, 2013. View at: Publisher Site | Google Scholar
  91. W. Zhang and X. He, “Microencapsulating and banking living cells for cell-based medicine,” Journal of Healthcare Engineering, vol. 2, no. 4, pp. 427–446, 2011. View at: Publisher Site | Google Scholar
  92. R. Calafiore and G. Basta, “Clinical application of microencapsulated islets: actual prospectives on progress and challenges,” Advanced Drug Delivery Reviews, vol. 67-68, pp. 84–92, 2014. View at: Publisher Site | Google Scholar
  93. S. V. Hegarty, G. W. O'Keeffe, and A. M. Sullivan, “Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson’s disease,” Neural Regeneration Research, vol. 9, no. 19, pp. 1708–1711, 2014. View at: Publisher Site | Google Scholar
  94. K. E. Haugstad, A. G. Håti, C. T. Nordgård et al., “Direct determination of chitosan—mucin interactions using a single-molecule strategy: comparison to alginate—mucin interactions,” Polymers, vol. 7, no. 2, pp. 161–185, 2015. View at: Publisher Site | Google Scholar
  95. G. Mythri, K. Kavitha, M. R. Kumar, and S. D. Jagadeesh Singh, “Novel mucoadhesive polymers—a review,” Journal of Applied Pharmaceutical Science, vol. 1, no. 8, pp. 37–42, 2011. View at: Google Scholar
  96. C. Taylor, J. P. Pearson, K. I. Draget, P. W. Dettmar, and O. Smidsrød, “Rheological characterisation of mixed gels of mucin and alginate,” Carbohydrate Polymers, vol. 59, no. 2, pp. 189–195, 2005. View at: Publisher Site | Google Scholar
  97. F. Laffleur, “Mucoadhesive polymers for buccal drug delivery,” Drug Development and Industrial Pharmacy, vol. 40, no. 5, pp. 591–598, 2014. View at: Publisher Site | Google Scholar
  98. C. Juliano, E. Gavini, M. Cossu, M. C. Bonferoni, and P. Giunchedi, “Mucoadhesive alginate matrices containing sodium carboxymethyl starch for buccal delivery: in vitro and in vivo studies,” Journal of Drug Delivery Science and Technology, vol. 14, no. 2, pp. 159–163, 2004. View at: Publisher Site | Google Scholar
  99. M. J. Martín, A. C. Calpena, F. Fernández, M. Mallandrich, P. Gálvez, and B. Clares, “Development of alginate microspheres as nystatin carriers for oral mucosa drug delivery,” Carbohydrate Polymers, vol. 117, pp. 140–149, 2015. View at: Publisher Site | Google Scholar
  100. S. Haque, S. Md, J. K. Sahni, J. Ali, and S. Baboota, “Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression,” Journal of Psychiatric Research, vol. 48, no. 1, pp. 1–12, 2014. View at: Publisher Site | Google Scholar
  101. R. J. Garmise, H. F. Staats, and A. J. Hickey, “Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination,” AAPS PharmSciTech, vol. 8, no. 4, pp. 2–10, 2007. View at: Google Scholar
  102. J. R. Costa, N. C. Silva, B. Sarmento, and M. Pintado, “Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 34, no. 6, pp. 1255–1262, 2015. View at: Publisher Site | Google Scholar
  103. Y. O. Batyrbekov, D. Rakhimbaeva, K. Musabekov, and B. Zhubanov, “Alginate based microparticle drug delivery systems for the treatment of eye cancer,” MRS Proceedings, vol. 1209, Article ID 1209-YY03-04, 2009. View at: Publisher Site | Google Scholar
  104. P. Diós, S. Nagy, S. Pál et al., “Preformulation studies and optimization of sodium alginate based floating drug delivery system for eradication of Helicobacter pylori,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 96, pp. 196–206, 2015. View at: Publisher Site | Google Scholar
  105. A. O. Adebisi, P. R. Laity, and B. R. Conway, “Formulation and evaluation of floating mucoadhesive alginate beads for targeting Helicobacter pylori,” Journal of Pharmacy and Pharmacology, vol. 67, no. 4, pp. 511–524, 2015. View at: Publisher Site | Google Scholar
  106. M. Szekalska, M. Wróblewska, K. Sosnowska, and K. Winnicka, “Influence of sodium alginate on hypoglycemic activity of metformin hydrochloride in the microspheres obtained by the spray drying,” International Journal of Polymer Science, vol. 2016, 12 pages, 2016. View at: Publisher Site | Google Scholar
  107. M. Szekalska, A. Amelian, and K. Winnicka, “Alginate microspheres obtained by the spray drying technique as mucoadhesive carriers of ranitidine,” Acta Pharmaceutica, vol. 65, no. 1, pp. 15–27, 2015. View at: Publisher Site | Google Scholar
  108. M. Szekalska, K. Winnicka, A. Czajkowska-Kośnik, K. Sosnowska, and A. Amelian, “Evaluation of alginate microspheres with metronidazole obtained by the spray drying technique,” Acta Poloniae Pharmaceutica—Drug Research, vol. 72, no. 3, pp. 569–578, 2015. View at: Google Scholar
  109. M. J. Martín-Villena, F. Fernández-Campos, A. C. Calpena-Campmany, N. Bozal-de Febrer, M. A. Ruiz-Martínez, and B. Clares-Naveros, “Novel microparticulate systems for the vaginal delivery of nystatin: development and characterization,” Carbohydrate Polymers, vol. 94, no. 1, pp. 1–11, 2013. View at: Publisher Site | Google Scholar
  110. A. Khare, K. Grover, P. Pawar, and I. Singh, “Mucoadhesive polymers for enhancing retention in ocular drug delivery: a critical review,” Reviews of Adhesion and Adhesives, vol. 2, no. 4, pp. 467–502, 2014. View at: Publisher Site | Google Scholar
  111. P. Prinderre, C. Sauzet, and C. Fuxen, “Advances in gastro retentive drug-delivery systems,” Expert Opinion on Drug Delivery, vol. 8, no. 9, pp. 1189–1203, 2011. View at: Publisher Site | Google Scholar
  112. A. A. Kharia and A. K. Singhai, “Screening of most effective variables for development of gastroretentive mucoadhesive nanoparticles by Taguchi design,” ISRN Nanomaterials, vol. 2013, 8 pages, 2013. View at: Publisher Site | Google Scholar
  113. O. Borges, J. Tavares, A. de Sousa, G. Borchard, H. E. Junginger, and A. Cordeiro-da-Silva, “Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles,” European Journal of Pharmaceutical Sciences, vol. 32, no. 4-5, pp. 278–290, 2007. View at: Publisher Site | Google Scholar
  114. F. Sarei, N. M. Dounighi, H. Zolfagharian, P. Khaki, and S. M. Bidhendi, “Alginate nanoparticles as a promising adjuvant and vaccine delivery system,” Indian Journal of Pharmaceutical Sciences, vol. 75, no. 4, pp. 442–449, 2013. View at: Publisher Site | Google Scholar
  115. P. Nyvall, E. Corre, C. Boisset et al., “Characterization of mannuronan C-5-epimerase genes from the brown alga Laminaria digitata,” Plant Physiology, vol. 133, no. 2, pp. 726–735, 2003. View at: Publisher Site | Google Scholar
  116. C. Campa, S. Holtan, N. Nilsen, T. M. Bjerkan, B. T. Stokke, and G. Skjåk-Bræk, “Biochemical analysis of the processive mechanism for epimerization of alginate by mannuronan C-5 epimerase AlgE4,” The Biochemical Journal, vol. 381, no. 1, pp. 155–164, 2004. View at: Publisher Site | Google Scholar
  117. J.-S. Yang, Y.-J. Xie, and W. He, “Research progress on chemical modification of alginate: a review,” Carbohydrate Polymers, vol. 84, no. 1, pp. 33–39, 2011. View at: Publisher Site | Google Scholar
  118. S. N. Pawar and K. J. Edgar, “Alginate derivatization: a review of chemistry, properties and applications,” Biomaterials, vol. 33, no. 11, pp. 3279–3305, 2012. View at: Publisher Site | Google Scholar
  119. T. W. Wong, “Alginate graft copolymers and alginate-co-excipient physical mixture in oral drug delivery,” The Journal of Pharmacy and Pharmacology, vol. 63, no. 12, pp. 1497–1512, 2011. View at: Publisher Site | Google Scholar
  120. S. W. Hutcheson, H. Zhang, and M. Suvorov, “Carbohydrase systems of Saccharophagus degradans degrading marine complex polysaccharides,” Marine Drugs, vol. 9, no. 4, pp. 645–665, 2011. View at: Publisher Site | Google Scholar
  121. E. Broderick, H. Lyons, T. Pembroke, H. Byrne, B. Murray, and M. Hall, “The characterisation of a novel, covalently modified, amphiphilic alginate derivative, which retains gelling and non-toxic properties,” Journal of Colloid and Interface Science, vol. 298, no. 1, pp. 154–161, 2006. View at: Publisher Site | Google Scholar
  122. H.-R. Lin, K. C. Sung, and W.-J. Vong, “In situ gelling of alginate/Pluronic solutions for ophthalmic delivery of pilocarpine,” Biomacromolecules, vol. 5, no. 6, pp. 2358–2365, 2004. View at: Publisher Site | Google Scholar
  123. G. Coşkun, E. Karaca, M. Ozyurtlu, S. Özbek, A. Yermezler, and I. Cavuşoğlu, “Histological evaluation of wound healing performance of electrospun poly(vinyl alcohol)/sodium alginate as wound dressing in vivo,” Bio-Medical Materials and Engineering, vol. 24, no. 2, pp. 1527–1536, 2014. View at: Publisher Site | Google Scholar
  124. A. A. Chang, M. S. Reuther, K. K. Briggs et al., “In vivo implantation of tissue-engineered human nasal septal neocartilage constructs: a pilot study,” Otolaryngology—Head and Neck Surgery, vol. 146, no. 1, pp. 46–52, 2012. View at: Publisher Site | Google Scholar
  125. S. Vériter, J. Mergen, R.-M. Goebbels et al., “In vivo selection of biocompatible alginates for islet encapsulation and subcutaneous transplantation,” Tissue Engineering Part A, vol. 16, no. 5, pp. 1503–1513, 2010. View at: Publisher Site | Google Scholar
  126. A. Sosnik, “Alginate particles as platform for drug delivery by the oral route: state-of-the-art,” ISRN Pharmaceutics, vol. 2014, Article ID 926157, 17 pages, 2014. View at: Publisher Site | Google Scholar
  127. Generally Recognized as Safe (Internet), “U.S. Food and Drug Administration,” View at: Google Scholar
  128. M. Otterlei, K. Østgaard, G. Skjåk-Bræk, O. Smidsrød, P. Soon-Shiong, and T. Espevik, “Induction of cytokine production from human monocytes stimulated with alginate,” The Journal of Immunotherapy, vol. 10, no. 4, pp. 286–291, 1991. View at: Publisher Site | Google Scholar
  129. M. Ménard, J. Dusseault, G. Langlois et al., “Role of protein contaminants in the immunogenicity of alginates,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, vol. 93, no. 2, pp. 333–340, 2010. View at: Publisher Site | Google Scholar
  130. M. Greco, C. A. Sáez, M. T. Brown, and M. B. Bitonti, “A simple and effective method for high quality co-extraction of genomic DNA and total RNA from low biomass Ectocarpus siliculosus, the model brown alga,” PLoS ONE, vol. 9, no. 5, Article ID e96470, 2014. View at: Publisher Site | Google Scholar
  131. L. Corvaglia, C. Monari, S. Martini, A. Aceti, and G. Faldella, “Pharmacological therapy of gastroesophageal reflux in preterm infants,” Gastroenterology Research and Practice, vol. 2013, Article ID 714564, 12 pages, 2013. View at: Publisher Site | Google Scholar
  132. F. C. Hampson, A. Farndale, V. Strugala, J. Sykes, I. G. Jolliffe, and P. W. Dettmar, “Alginate rafts and their characterisation,” International Journal of Pharmaceutics, vol. 294, no. 1-2, pp. 137–147, 2005. View at: Publisher Site | Google Scholar
  133. DrugBank Database (Internet), University of Alberta, Canada,
  134. K. G. Mandel, B. P. Daggy, D. A. Brodie, and H. I. Jacoby, “Review article: alginate-raft formulations in the treatment of heartburn and acid reflux,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 6, pp. 669–690, 2000. View at: Publisher Site | Google Scholar
  135. N. Yavorska, “Sodium alginate—a potential tool for weight management: effect on subjective appetite, food intake, and glycemic and insulin regulation,” Journal of Undergraduate Life Sciences, vol. 6, no. 1, pp. 66–69, 2012. View at: Google Scholar
  136. J. A. Williams, C. S. Lai, H. Corwin et al., “Inclusion of guar gum and alginate into a crispy bar improves postprandial glycemia in human,” The Journal of Nutrition, vol. 134, no. 4, pp. 886–889, 2004. View at: Google Scholar
  137. B. W. Wolf, C.-S. Lai, M. S. Kipnes et al., “Glycemic and insulinemic responses of nondiabetic healthy adult subjects to an experimental acid-induced viscosity complex incorporated into a glucose beverage,” Nutrition, vol. 18, no. 7-8, pp. 621–626, 2002. View at: Publisher Site | Google Scholar
  138. I. Torsdottir, M. Alpsten, G. Holm, A.-S. Sandberg, and J. Tolli, “A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes,” The Journal of Nutrition, vol. 121, no. 6, pp. 795–799, 1991. View at: Google Scholar
  139. C. A. Tarling, K. Woods, R. Zhang et al., “The search for novel human pancreatic α-amylase inhibitors: high-throughput screening of terrestrial and marine natural product extracts,” ChemBioChem, vol. 9, no. 3, pp. 433–438, 2008. View at: Publisher Site | Google Scholar
  140. Y. Idota, Y. Kogure, T. Kato et al., “Cholesterol-lowering effect of calcium alginate in rats,” Biological & Pharmaceutical Bulletin, vol. 39, no. 1, pp. 62–67, 2016. View at: Publisher Site | Google Scholar
  141. J. R. Paxman, J. C. Richardson, P. W. Dettmar, and B. M. Corfe, “Alginate reduces the increased uptake of cholesterol and glucose in overweight male subjects: a pilot study,” Nutrition Research, vol. 28, no. 8, pp. 501–505, 2008. View at: Publisher Site | Google Scholar
  142. Y. Kimura, K. Watanabe, and H. Okuda, “Effects of soluble sodium alginate on cholesterol excretion and glucose tolerance in rats,” Journal of Ethnopharmacology, vol. 54, no. 1, pp. 47–54, 1996. View at: Publisher Site | Google Scholar
  143. M. Georg Jensen, C. Pedersen, M. Kristensen, G. Frost, and A. Astrup, “Review: efficacy of alginate supplementation in relation to appetite regulation and metabolic risk factors: evidence from animal and human studies,” Obesity Reviews, vol. 14, no. 2, pp. 129–144, 2013. View at: Publisher Site | Google Scholar
  144. D. Houghton, M. D. Wilcox, P. I. Chater, I. A. Brownlee, C. J. Seal, and J. P. Pearson, “Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity,” Food Hydrocolloids, vol. 49, pp. 18–24, 2015. View at: Publisher Site | Google Scholar
  145. D.-H. Ngo and S.-K. Kim, “Sulfated polysaccharides as bioactive agents from marine algae,” International Journal of Biological Macromolecules, vol. 62, pp. 70–75, 2013. View at: Publisher Site | Google Scholar
  146. J.-B. Lee, A. Takeshita, K. Hayashi, and T. Hayashi, “Structures and antiviral activities of polysaccharides from Sargassum trichophyllum,” Carbohydrate Polymers, vol. 86, no. 2, pp. 995–999, 2011. View at: Publisher Site | Google Scholar
  147. G. L. Yan, Y. M. Guo, J. M. Yuan, D. Liu, and B. K. Zhang, “Sodium alginate oligosaccharides from brown algae inhibit Salmonella enteritidis colonization in broiler chickens,” Poultry Science, vol. 90, no. 7, pp. 1441–1448, 2011. View at: Publisher Site | Google Scholar
  148. S. Benavides, R. Villalobos-Carvajal, and J. E. Reyes, “Physical, mechanical and antibacterial properties of alginate film: effect of the crosslinking degree and oregano essential oil concentration,” Journal of Food Engineering, vol. 110, no. 2, pp. 232–239, 2012. View at: Publisher Site | Google Scholar
  149. E.-W. Son, D.-K. Rhee, and S. Pyo, “Antiviral and tumoricidal activities of alginate-stimulated macrophages are mediated by different mechanisms,” Archives of Pharmacal Research, vol. 26, no. 11, pp. 960–966, 2003. View at: Publisher Site | Google Scholar
  150. A. Ahmadi, S. Z. Moghadamtousi, S. Abubakar, and K. Zandi, “Antiviral potential of algae polysaccharides isolated from marine sources: a review,” BioMed Research International, vol. 2015, Article ID 825203, 10 pages, 2015. View at: Publisher Site | Google Scholar
  151. S.-X. Wang, X.-S. Zhang, H.-S. Guan, and W. Wang, “Potential anti-HPV and related cancer agents from marine resources: an overview,” Marine Drugs, vol. 12, no. 4, pp. 2019–2035, 2014. View at: Publisher Site | Google Scholar
  152. Y. Sano, “Antiviral activity of alginate against infection by tobacco mosaic virus,” Carbohydrate Polymers, vol. 38, no. 2, pp. 183–186, 1999. View at: Publisher Site | Google Scholar
  153. M. Witvrouw and E. De Clercq, “Sulfated polysaccharides extracted from sea algae as potential antiviral drugs,” General Pharmacology, vol. 29, no. 4, pp. 497–511, 1997. View at: Publisher Site | Google Scholar
  154. G. Meiyu, L. Fuchuan, X. Xianliang, L. Jing, Y. Zuowei, and G. Huashi, “The potential molecular targets of marine sulfated polymannuroguluronate interfering with HIV-1 entry. Interaction between SPMG and HIV-1 rgp120 and CD4 molecule,” Antiviral Research, vol. 59, no. 2, pp. 127–135, 2003. View at: Publisher Site | Google Scholar
  155. E. H. Son, E. Y. Moon, D. K. Rhee, and S. Pyo, “Stimulation of various functions in murine peritoneal macrophages by high mannuronic acid–containing alginate (HMA) exposure in vivo,” International Immunopharmacology, vol. 1, no. 1, pp. 147–154, 2001. View at: Publisher Site | Google Scholar
  156. Z.-A. Yao, H.-G. Wu, B.-Q. Han, H.-M. Ma, Z.-F. Jiang, and Y.-G. Du, “The antithrombotic action of propylene glycol mannite sulfate (PGMS),” Pharmacological Research, vol. 53, no. 2, pp. 166–170, 2006. View at: Publisher Site | Google Scholar
  157. A. K. Taşkın, M. Yaşar, I. Ozaydın et al., “The hemostatic effect of calcium alginate in experimental splenic injury model,” Turkish Journal of Trauma & Emergency Surgery, vol. 19, no. 3, pp. 195–199, 2013. View at: Publisher Site | Google Scholar
  158. H. Hattori, Y. Amano, Y. Nogami, B. Takase, and M. Ishihara, “Hemostasis for severe hemorrhage with photocrosslinkable chitosan hydrogel and calcium alginate,” Annals of Biomedical Engineering, vol. 38, no. 12, pp. 3724–3732, 2010. View at: Publisher Site | Google Scholar
  159. K. Kaneda, S. Kuroda, N. Goto, D. Sato, K. I. Ohya, and S. Kasugai, “Is sodium alginate an alternative hemostatic material in the tooth extraction socket?” Journal of Oral Tissue Engineering, vol. 5, no. 3, pp. 127–133, 2007. View at: Publisher Site | Google Scholar
  160. Y. Zeng, D. Yang, P. Qiu et al., “Efficacy of Heparinoid PSS in treating cardiovascular diseases and beyond—a review of 27 years clinical experiences in China,” Clinical and Applied Thrombosis/Hemostasis, vol. 22, no. 3, pp. 222–229, 2016. View at: Publisher Site | Google Scholar
  161. Y.-Y. Chen, W. Ji, J.-R. Du et al., “Preventive effects of low molecular mass potassium alginate extracted from brown algae on DOCA salt-induced hypertension in rats,” Biomedicine & Pharmacotherapy, vol. 64, no. 4, pp. 291–295, 2010. View at: Publisher Site | Google Scholar
  162. M. C. Rocha De Souza, C. T. Marques, C. M. Guerra Dore, F. R. Ferreira Da Silva, H. A. Oliveira Rocha, and E. L. Leite, “Antioxidant activities of sulfated polysaccharides from brown and red seaweeds,” Journal of Applied Phycology, vol. 19, no. 2, pp. 153–160, 2007. View at: Publisher Site | Google Scholar
  163. F. Namvar, R. Mohamad, J. Baharara, S. Zafar-Balanejad, F. Fargahi, and H. S. Rahman, “Antioxidant, antiproliferative, and antiangiogenesis effects of polyphenol-rich seaweed (Sargassum muticum),” BioMed Research International, vol. 2013, Article ID 604787, 9 pages, 2013. View at: Publisher Site | Google Scholar
  164. Y. Yamamoto, M. Kurachi, K. Yamaguchi, and T. Oda, “Stimulation of multiple cytokine production in mice by alginate oligosaccharides following intraperitoneal administration,” Carbohydrate Research, vol. 342, no. 8, pp. 1133–1137, 2007. View at: Publisher Site | Google Scholar
  165. T. I. Imbs, S. P. Ermakova, O. S. Malyarenko (Vishchuk), V. V. Isakov, and T. N. Zvyagintseva, “Structural elucidation of polysaccharide fractions from the brown alga Coccophora langsdorfii and in vitro investigation of their anticancer activity,” Carbohydrate Polymers, vol. 135, pp. 162–168, 2016. View at: Publisher Site | Google Scholar
  166. D. Maciel, P. Figueira, S. Xiao et al., “Redox-responsive alginate nanogels with enhanced anticancer cytotoxicity,” Biomacromolecules, vol. 14, no. 9, pp. 3140–3146, 2013. View at: Publisher Site | Google Scholar
  167. H.-J. Jeong, S.-A. Lee, P.-D. Moon et al., “Alginic acid has anti-anaphylactic effects and inhibits inflammatory cytokine expression via suppression of nuclear factor-κB activation,” Clinical and Experimental Allergy, vol. 36, no. 6, pp. 785–794, 2006. View at: Publisher Site | Google Scholar
  168. T. Uno, M. Hattori, and T. Yoshida, “Oral administration of alginic acid oligosaccharide suppresses IgE production and inhibits the induction of oral tolerance,” Bioscience, Biotechnology and Biochemistry, vol. 70, no. 12, pp. 3054–3057, 2006. View at: Publisher Site | Google Scholar
  169. A. B. A. Ahmed, M. Adel, P. Karimi, and M. Peidayesh, “Chapter ten—pharmaceutical, cosmeceutical, and traditional applications of marine carbohydrates,” Advances in Food and Nutrition Research, vol. 73, pp. 197–220, 2014. View at: Publisher Site | Google Scholar
  170. T. Andersen, C. Markussen, M. Dornish et al., “In situ gelation for cell immobilization and culture in alginate foam scaffolds,” Tissue Engineering Part A, vol. 20, no. 3-4, pp. 600–610, 2014. View at: Publisher Site | Google Scholar
  171. H. Geckil, F. Xu, X. Zhang, S. Moon, and U. Demirci, “Engineering hydrogels as extracellular matrix mimics,” Nanomedicine, vol. 5, no. 3, pp. 469–484, 2010. View at: Publisher Site | Google Scholar
  172. C. Godugu and M. Singh, “AlgiMatrix™-based 3D cell culture system as an in vitro tumor model: an important tool in cancer research,” in Cancer Chemoprevention, vol. 1379 of Methods in Molecular Biology, pp. 117–128, Springer, 2016. View at: Publisher Site | Google Scholar
  173. T. Andersen, P. Auk-Emblem, and M. Dornish, “3D cell culture in alginate hydrogels,” Microarrays, vol. 4, no. 2, pp. 133–161, 2015. View at: Publisher Site | Google Scholar
  174. C. Godugu, A. R. Patel, U. Desai, T. Andey, A. Sams, and M. Singh, “AlgiMatrix™ based 3D cell culture system as an in-vitro tumor model for anticancer studies,” PLoS ONE, vol. 8, no. 1, Article ID e53708, 2013. View at: Publisher Site | Google Scholar
  175. S. J. M. Skinner, M. S. Geaney, H. Lin et al., “Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma,” Journal of Neural Engineering, vol. 6, no. 6, Article ID 065001, 2009. View at: Publisher Site | Google Scholar
  176. L. N. Pettingill, A. K. Wise, M. S. Geaney, and R. K. Shepherd, “Enhanced auditory neuron survival following cell-based BDNF treatment in the deaf guinea pig,” PLoS ONE, vol. 6, no. 4, Article ID e18733, 2011. View at: Publisher Site | Google Scholar
  177. H. K. Yang and K.-H. Yoon, “Current status of encapsulated islet transplantation,” Journal of Diabetes and its Complications, vol. 29, no. 5, pp. 737–743, 2015. View at: Publisher Site | Google Scholar
  178. A. L. Hillberg, K. Kathirgamanathan, J. B. Lam, L. Y. Law, O. Garkavenko, and R. B. Elliott, “Improving alginate-poly-L-ornithine-alginate capsule biocompatibility through genipin crosslinking,” Journal of Biomedical Materials Research—Part B Applied Biomaterials, vol. 101, no. 2, pp. 258–268, 2013. View at: Publisher Site | Google Scholar
  179. M. Qi, “Transplantation of encapsulated pancreatic islets as a treatment for patients with type 1 diabetes mellitus,” Advances in Medicine, vol. 2014, Article ID 429710, 15 pages, 2014. View at: Publisher Site | Google Scholar
  180. J. Schweicher, C. Nyitray, and T. A. Desai, “Membranes to achieve immunoprotection of transplanted islets,” Frontiers in Bioscience, vol. 19, no. 1, pp. 49–76, 2014. View at: Publisher Site | Google Scholar
  181. Clinical trials (Internet), U.S. National Institutes of Health,
  182. S. Irving, L. Gillespie, R. Richardson, D. Rowe, J. B. Fallon, and A. K. Wise, “Electroacoustic stimulation: now and into the future,” BioMed Research International, vol. 2014, Article ID 350504, 17 pages, 2014. View at: Publisher Site | Google Scholar
  183. European Parkinson’s Disease Association (Internet),
  184. L. C. Powell, A. Sowedan, S. Khan et al., “The effect of alginate oligosaccharides on the mechanical properties of Gram-negative biofilms,” Biofouling, vol. 29, no. 4, pp. 413–421, 2013. View at: Publisher Site | Google Scholar
  185. W. Hengzhuang, Z. Song, O. Ciofu, E. Onsøyen, P. D. Rye, and N. Høiby, “OligoG CF-5/20 disruption of mucoid Pseudomonas aeruginosa biofilm in a murine lung infection model,” Antimicrobial Agents and Chemotherapy, vol. 60, no. 5, pp. 2620–2626, 2016. View at: Publisher Site | Google Scholar
  186. A. Tøndervik, H. Sletta, G. Klinkenberg et al., “Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals against Candida and Aspergillus spp.,” PLoS ONE, vol. 9, no. 11, Article ID e112518, 2014. View at: Publisher Site | Google Scholar
  187. S. Chaluvadi, A. T. Hotchkiss Jr., J. E. Call et al., “Protection of probiotic bacteria in a synbiotic matrix following aerobic storage at 4 °C,” Beneficial Microbes, vol. 3, no. 3, pp. 175–187, 2012. View at: Publisher Site | Google Scholar

Copyright © 2016 Marta Szekalska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.